Leadscope(R) Inc. to Introduce New Server-Based Software Solution at IBC's Drug Discovery Technology 2001

Apr 18, 2001, 01:00 ET from LeadScope Inc.

    COLUMBUS, Ohio, April 18 /PRNewswire/ -- Europe's largest
 multidisciplinary biopharmaceutical conference will be the setting for
 LeadScope Inc.'s unveiling of their latest innovative software solution-
 LeadScope(R) Enterprise.  IBC's Drug Discovery Technology 2001 is set for
 April 23-26 in Stuttgart, Germany.  This high-profile conference will bring
 together more than 55 speakers, 80 exhibitors, and 850 participants to focus
 on the major strategic, technological, and partnering challenges facing the
 biopharmaceutical industry.
     Since 1997, LeadScope Inc. has focused on creating chemically intelligent
 decision-support software that meets the changing needs of life scientists.
 LeadScope Enterprise addresses the needs for high-capacity, industry-scale
 data analysis and visualization tools to speed the process and cut the high
 costs of drug discovery.
     The new server-based decision-support software solution promises seamless
 access to corporate data, along with chemically based data-mining and
 visualization capabilities.  Companies will now have the ability to share
 knowledge throughout their organization via an enterprise server.
     "The LeadScope team has been working closely with our beta sites,"
 explains Wayne Johnson, VP Development.  "This collaborative effort has
 resulted in a system that's capable of integrating chemical and biological
 screening data throughout a worldwide organization.  The unique
 chemoinformatics platform of LeadScope Enterprise dramatically decreases
 development time, shortening the time required for certain processes from
 months to hours, and improves the quality of research decisions."
     LeadScope will be sharing details about the new software at the Drug
 Discovery Technology 2001 Conference, and will be inviting participants to be
 a part of their upcoming worldwide launch demonstration.
     LeadScope is currently working to incorporate data from other areas of
 drug discovery and development, including toxicology and genomics.  Other new
 products on the horizon include ToxScope(TM), a series of toxicity databases
 to be released at the same time as LeadScope Enterprise, and GeneScope(TM), a
 gene expression analysis and chemical genomics system planned to be released
 in 2002.  LeadScope will also continue to offer Personal LeadScope(R), the
 desktop version of the decision-support software.  Personal LeadScope is
 currently used by more than 32 leading pharmaceutical and biotechnical sites
 to speed drug discovery and eliminate unnecessary costs.
     LeadScope's ( http://www.leadscope.com ) expertise includes an in-depth
 knowledge of advanced informatics technology and the services necessary to
 help organizations effectively extract and visualize the valuable knowledge
 contained in research data.  LeadScope Inc. is dedicated to working with their
 customers to shorten drug development time and dramatically increase the
 quality of research decisions.
 
 

SOURCE LeadScope Inc.
    COLUMBUS, Ohio, April 18 /PRNewswire/ -- Europe's largest
 multidisciplinary biopharmaceutical conference will be the setting for
 LeadScope Inc.'s unveiling of their latest innovative software solution-
 LeadScope(R) Enterprise.  IBC's Drug Discovery Technology 2001 is set for
 April 23-26 in Stuttgart, Germany.  This high-profile conference will bring
 together more than 55 speakers, 80 exhibitors, and 850 participants to focus
 on the major strategic, technological, and partnering challenges facing the
 biopharmaceutical industry.
     Since 1997, LeadScope Inc. has focused on creating chemically intelligent
 decision-support software that meets the changing needs of life scientists.
 LeadScope Enterprise addresses the needs for high-capacity, industry-scale
 data analysis and visualization tools to speed the process and cut the high
 costs of drug discovery.
     The new server-based decision-support software solution promises seamless
 access to corporate data, along with chemically based data-mining and
 visualization capabilities.  Companies will now have the ability to share
 knowledge throughout their organization via an enterprise server.
     "The LeadScope team has been working closely with our beta sites,"
 explains Wayne Johnson, VP Development.  "This collaborative effort has
 resulted in a system that's capable of integrating chemical and biological
 screening data throughout a worldwide organization.  The unique
 chemoinformatics platform of LeadScope Enterprise dramatically decreases
 development time, shortening the time required for certain processes from
 months to hours, and improves the quality of research decisions."
     LeadScope will be sharing details about the new software at the Drug
 Discovery Technology 2001 Conference, and will be inviting participants to be
 a part of their upcoming worldwide launch demonstration.
     LeadScope is currently working to incorporate data from other areas of
 drug discovery and development, including toxicology and genomics.  Other new
 products on the horizon include ToxScope(TM), a series of toxicity databases
 to be released at the same time as LeadScope Enterprise, and GeneScope(TM), a
 gene expression analysis and chemical genomics system planned to be released
 in 2002.  LeadScope will also continue to offer Personal LeadScope(R), the
 desktop version of the decision-support software.  Personal LeadScope is
 currently used by more than 32 leading pharmaceutical and biotechnical sites
 to speed drug discovery and eliminate unnecessary costs.
     LeadScope's ( http://www.leadscope.com ) expertise includes an in-depth
 knowledge of advanced informatics technology and the services necessary to
 help organizations effectively extract and visualize the valuable knowledge
 contained in research data.  LeadScope Inc. is dedicated to working with their
 customers to shorten drug development time and dramatically increase the
 quality of research decisions.
 
 SOURCE  LeadScope Inc.